



The information contained in the present announcement is considered to be in the public domain since the date release of this letter.

Friday October 23, 2020

COPPTECH ANTIMICROBIAL SOLUTIONS

Successful tests against SARS-CoV-2

COPPTECH is very much pleased to announce that during the months of September and October 2020 a first series of tests against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the COVID-19 causing virus, were performed on materials treated with COPPTECH antimicrobial technology.

The tests were carried out by the Southampton University laboratory, one of the leading investigation institutions in United Kingdom and Europe and according to:


1. ISO Standards.
2. Best Laboratory Practices.

Due to the importance of knowing the performance & efficacy of the technology the tests on both series are and will be performed on different timescales.

The tests reveal an efficacy of up to 99% SARS-CoV-2 inactivation after 2 hours in contact with some surfaces or materials treated with Copptech technology.

Copptech is aware about how critical is to provide new solutions to different industries in order to reduce the persistence of the SARS-CoV-2 in any surface.

The following chart provides a good comparison of persistence depending on the surface material.



(Sources: papers available to public released by CSIRO, NEJM, etc....)

Francisco Silberberg, CEO and founder of COPPTECH said: “Our recent tests related to SARS-CoV-2, and therefore to COVID-19, are incredible news for COPPTECH and for our clients in different countries of the world. The successful performance of the COPPTECH technology confirms what we already suspected: COPPTECH technology has a comprehensive antimicrobial solution spectrum”.

Beside the excellent results achieved by the tests, COPPTECH is equally proud of having them performed by a well-known institution like Southampton University under the supervision of Professor Bill Keevil (Head of the Microbiology Group and Director of the Environmental Healthcare Unit).

<https://www.southampton.ac.uk/biosci/about/staff/cwk.page#research>

COPPTECH will keep our partners updated about the new series of tests in the coming months.

For further inquires about COPPTECH technology and application, specially those related to USA due to its antiviral claims policy, COPPTECH team remains always at your disposal.

No limits for wellbeing

